Uri Geiger Buys Shares of NPCE $NPCE

Key Points

  • Uri Geiger bought 789 shares of NeuroPace, Inc. ($NPCE) worth $12,332.07.
  • $NPCE last traded around $15.37.

Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.

Uri Geiger, insider at NeuroPace, Inc. ($NPCE), bought 789 shares at an average price of $15.63, for a total transaction of $12,332.07. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission.

NeuroPace, Inc. Stock Up 6.7%

Shares of NeuroPace, Inc. ($NPCE) traded around $15.37 on Tuesday, up 6.7% for the day.

Last price$15.37
Market cap$502.85M
Forward P/E-65.94
Beta1.94
52-week low$8.88
52-week high$19.60
50-day MA$15.20
200-day MA$15.44
Current ratio4.94
Quick ratio3.82
Debt-to-equity5.88

NeuroPace, Inc. Earnings

EPS (ttm)-$0.47
Revenue (ttm)$106.99M
Revenue growth17.10%
Net margin-17.86%
Return on equity-103.27%
Next earningsNov 3, 2026

Analysts Set New Price Targets

Average target$20.22
High target$22
Low target$18
Analysts covering9

About NeuroPace, Inc.

NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet which is used for prescribing and managing clinicians for programming implanted devices and managing patient care; and patient data management system, a secure online database that collects data that have been recorded by the RNS System; and nSight Platform, which provide clinicians with personalized patient reports, as well as programming suggestions. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.

ExchangeNasdaqGM
SectorHealthcare
IndustryMedical Devices
HeadquartersMountain View, CA
CEOMr. Joel D. Becker
Employees220

Get NeuroPace, Inc. alerts

New 13F filings, insider trades, and analyst moves on $NPCE, sent to your inbox. Free, and you can unsubscribe anytime.

This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.